Omer Shahab, Mehmet Sayiner, James Paik, Sean Felix, Pegah Golabi, Zobair M. Younossi – 28 January 2019 – Primary biliary cholangitis (PBC) is an autoimmune liver disease that can lead to cirrhosis and liver failure. Our aim was to assess the recent trends in the mortality rates and health care utilization of patients with PBC seen in the inpatient setting in the United States. We used the National (Nationwide) Inpatient Sample data (2005‐2014). The study population included adults with PBC, using International Classification of Diseases, Ninth Revision codes.

Camillo Porta, Chiara Broglia, Francesca Negri – 25 January 2019

Ana C. Maretti‐Mira, Laurie D. DeLeve – 25 January 2019

Liguo Wang, George W. Marek, Ryan A. Hlady, Ryan T. Wagner, Xia Zhao, Virginia C. Clark, Alex Xiucheng Fan, Chen Liu, Mark Brantly, Keith D. Robertson – 25 January 2019 – Alpha‐1 antitrypsin deficiency (AATD) liver disease is characterized by marked heterogeneity in presentation and progression, despite a common underlying gene mutation, strongly suggesting the involvement of other genetic and/or epigenetic modifiers. Variation in clinical phenotype has added to the challenge of detection, diagnosis, and testing of new therapies in patients with AATD.

Seung‐Jin Kim, Dechun Feng, Adrien Guillot, Shen Dai, Fengming Liu, Seonghwan Hwang, Richard Parker, Wonhyo Seo, Yong He, Grzegorz Godlewski, Won‐Il Jeong, Yuhong Lin, Xuebin Qin, George Kunos, Bin Gao – 25 January 2019 – Adipocyte death occurs under various physiopathological conditions, including obesity and alcohol drinking, and can trigger organ damage particularly in the liver, but the underlying mechanisms remain obscure.

Liguo Wang, George W. Marek, Ryan A. Hlady, Ryan T. Wagner, Xia Zhao, Virginia C. Clark, Alex Xiucheng Fan, Chen Liu, Mark Brantly, Keith D. Robertson – 25 January 2019 – Alpha‐1 antitrypsin deficiency (AATD) liver disease is characterized by marked heterogeneity in presentation and progression, despite a common underlying gene mutation, strongly suggesting the involvement of other genetic and/or epigenetic modifiers. Variation in clinical phenotype has added to the challenge of detection, diagnosis, and testing of new therapies in patients with AATD.

Grace Lai‐Hung Wong, Lilian Yan Liang, Raymond Kwok, Aric Josun Hui, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Vincent Wai‐Sun Wong – 25 January 2019 – We previously demonstrated the possible noninferiority of a screening strategy for varices guided by liver and spleen stiffness measurement (LSSM) compared to universal endoscopic screening in detecting clinically significant varices in patients with cirrhosis. We now report the long‐term outcome of the patients recruited in this trial for incident variceal bleeding and other hepatic events.

Heidi Yeh, Korkut Uygun – 25 January 2019

Hiam Chemaitelly, Sarwat Mahmud, Silva P. Kouyoumjian, Zaina Al‐Kanaani, Joumana G. Hermez, Laith J. Abu‐Raddad – 23 January 2019 – Expanding hepatitis C virus (HCV) treatment coverage is challenged by limited testing and diagnosis. This study assessed the risk of exposure, for the Middle East and North Africa, by population, yields of testing, and program efficiency of testing strategies. A standardized and systematically assembled database of 2,542 HCV antibody prevalence studies on 49 million individuals was analyzed.

Mohammad Bilal Siddiqui, Tamoore Arshad, Samarth Patel, Emily Lee, Somaya Albhaisi, Arun J. Sanyal, R. Todd Stravitz, Carolyn Driscoll, Richard K. Sterling, Trevor Reichman, Chandra Bhati, Mohammad Shadab Siddiqui – 23 January 2019 – Cardiovascular disease (CVD) is an important cause of morbidity and mortality after liver transplantation (LT). Although LT is associated with dyslipidemia, particularly atherogenic lipoprotein subparticles, the impact of these subparticles on CVD‐related events is unknown.